VOGLIBOSE 0.2mg. IP + METFORMIN 500mg. IP

A combination of antidiabetic medicines that helps to control high blood sugar levels. Inhibits the post-prandial increase in blood glucose levels in people with diabetes mellitus. (Hyang-Ki Choi, 2015) Delays the digestion as well as absorption of carbohydrates and inhibits postprandial hyperglycemia. (Xiaolong Chen, 2006) Reduces the development of type 2 diabetes in high-risk individuals with impaired glucose tolerance. (Ryuzo Kawamori, 2009) A safe antihyperglycemic agent that effectively controls blood glucose levels. (Tae Jung Oh, 2019) Shows higher HbA1c reduction, lower glycemic variability less gastrointestinal adverse events and higher weight loss than metformin monotherapy. (Sohn, 2019) Delays the onset of vascular complications in patients with type 2 diabetes. (N Saito, 1998) A good option in initial therapy for subjects with type 2 diabetes mellitus. (Tae Jung Oh J. M., 2019) An alternative therapeutic option for patients with Type 2 diabetes mellitus in which glycemic control is inadequate. (Ajay S. Dabhi, 2013) An effective and well-tolerated drug in a wide range of type 2 diabetic mellitus patients. (Ajay S. Dabhi, 2013) More effective option for overweight or obese individuals with type 2 diabetes. (Tae Jung Oh J. M., 2019)